Leflunomida Pharmathen (Leflunomide)

Leflunomide blocks the enzyme dihydroorotate dehydrogenase, which is essential for de novo pyrimidine synthesis. By limiting pyrimidine production, the drug suppresses the proliferation of activated lymphocytes, thereby dampening the autoimmune response that drives inflammation in rheumatoid and psoriatic arthritis.

The specific dose of Leflunomida Pharmathen is determined by the prescribing physician based on the individual patient's clinical condition, disease severity, and response to therapy. Dosing decisions are made by the healthcare professional and should not be altered without medical guidance.

Leflunomida Pharmathen is classified as pregnancy category X, meaning it is contraindicated in pregnancy due to a high risk of fetal malformations. It is also not recommended for breastfeeding mothers because the drug can be excreted in breast milk and may harm the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Leflunomide offers oral administration and a distinct mechanism—blocking pyrimidine synthesis—compared with biologic DMARDs that target specific cytokines. It is often used when methotrexate is insufficient or not tolerated, but its safety profile, especially liver and teratogenic risks, differs and must be considered.

Leflunomida Pharmathen should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Keeping the product in a dry, cool environment helps maintain its stability and potency throughout its shelf life.

Leflunomida Pharmathen is taken orally, usually as a tablet swallowed whole with water. The exact timing and whether it should be taken with food are determined by the prescribing physician, who will provide instructions tailored to the patient’s regimen.

The most serious risks include severe liver injury, bone‑marrow suppression leading to pancytopenia, pulmonary toxicity such as interstitial lung disease, and teratogenic effects that can cause fetal malformations. Patients should be monitored regularly for liver enzymes, blood counts, and respiratory symptoms.

Leflunomida Pharmathen is contraindicated in pregnant women, individuals with severe liver impairment, active infections, or known hypersensitivity to leflunomide. It should also be avoided in patients with uncontrolled hypertension or those receiving live vaccines without appropriate medical supervision.